ReviewRheumatology international2015
Role of osteopontin in rheumatoid arthritis.
Review in Rheumatology international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Clinical significance of microRNA-328-3p and bone metabolism biomarkers in gout patients with different musculoskeletal ultrasonography imaging.Journal of orthopaedic surgery and research · 2025Article
- Osteopontin inhibits autophagy via CD44 and avβ3 integrin and promotes cell proliferation in osteoarthritic fibroblast-like synoviocytes.BMC musculoskeletal disorders · 2025Article
- The chromatin landscape of pathogenic transcriptional cell states in rheumatoid arthritis.Nature communications · 2024Article
- Immunoregulatory Roles of Osteopontin in Diseases.Nutrients · 2024Review
- Identification of novel biomarkers for the prediction of subclinical coronary artery atherosclerosis in patients with rheumatoid arthritis: an exploratory analysis.Arthritis research & therapy · 2023Article
- The Chromatin Landscape of Pathogenic Transcriptional Cell States in Rheumatoid Arthritis.bioRxiv : the preprint server for biology · 2023Article
- The Role and Clinical Relevance of Osteopontin in Allergic Airway Diseases.Journal of clinical medicine · 2023Review
- Baseline Plasma Osteopontin Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients.Viruses · 2023Observational
- Identification of anti-citrullinated osteopontin antibodies and increased inflammatory response by enhancement of osteopontin binding to fibroblast-like synoviocytes in rheumatoid arthritis.Arthritis research & therapy · 2023Article
- Organokines in Rheumatoid Arthritis: A Critical Review.International journal of molecular sciences · 2022Review
- Osteopontin in autoimmune disorders: current knowledge and future perspective.Inflammopharmacology · 2022Review
- Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications.Stem cells international · 2022Review
- Osteopontin and Transplantation: Where Are We Now?Archivum immunologiae et therapiae experimentalis · 2021Review
- Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities.Scientific reports · 2018Article
- Traditional Chinese medicine formula Bi-Qi capsule alleviates rheumatoid arthritis-induced inflammation, synovial hyperplasia, and cartilage destruction in rats.Arthritis research & therapy · 2018Article
- Adiponectin aggravates bone erosion by promoting osteopontin production in synovial tissue of rheumatoid arthritis.Arthritis research & therapy · 2018Article
- Endogenous bone morphogenetic protein 2 plays a role in vascular smooth muscle cell calcification induced by interleukin 6 in vitro.International journal of immunopathology and pharmacology · 2017Article
- T Cells in Osteoarthritis: Alterations and Beyond.Frontiers in immunology · 2017Review
- Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.Advanced drug delivery reviews · 2016Review
- Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases.Journal of immunology research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling, joint tenderness, and destruction of synovial joints, leading to severe disability and premature mortality. RA is a multifactorial disease with genetic, environmental, and stochastic components related to its susceptibility. It has been demonstrated that the expression of osteopontin (OPN) is upregulated in the RA patients. Numerous studies have indicated that the full-length OPN or even OPN fragments, such as thrombin-cleaved OPN and its receptors, play the key roles in RA pathogenesis. Therapeutic application of siRNA to target OPN or neutralizing antibodies related to OPN epitopes in RA animal models are in progress, and some results are encouraging. However, there is a long way to go along with the clinical trials. This review focuses on the recent development in research associated with the OPN role in the pathogenesis of RA and provides insights concerning the OPN targeting as therapeutic approaches for patients with RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.